Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Biodefense Stories

2010-11-09 07:30:00

CHICAGO, Nov. 9, 2010 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has submitted a full proposal to the National Institute of Allergy and Infectious Diseases (NIAID) under BAA-NIAID-DMID-NIHAI2010097 Development Of Therapeutics For Biodefense. It is...

2010-11-02 06:00:00

PRINCETON, N.J., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, reported today that it has completed enrollment of its Phase 1B clinical trial of RiVax(TM), a ricin subunit vaccine, in healthy volunteers. Preliminary results indicate that RiVax(TM) appears safe at all doses tested in volunteers. This trial is designed to assess the duration of immune responses using an adjuvant formulation...

2010-10-21 09:22:00

ANNAPOLIS, Md., Oct. 21 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company's Board of Directors has appointed Eric I. Richman to the position of President and Chief Executive Officer, effective immediately. Mr. Richman was previously appointed President and Interim Chief Executive Officer in May 2010, and prior thereto served as the Company's...

2010-10-08 02:00:45

Research to focus on improving delivery of dengue and anthrax vaccines The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced three new contracts to fund research on vaccines to protect against emerging infectious diseases and biological threats that could be used in a terror attack. Each project focuses on simple and efficient vaccine delivery approaches that could be deployed quickly. The total funding for the three...

2010-10-04 08:00:00

CHICAGO, Oct. 4 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the company provided testimony at the U.S. Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services (HHS) Hearing on "Defending Against Public Health Threats" on...

2010-09-02 07:00:00

PRINCETON, N.J., Sept. 2 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today the publication of an article online in Vaccine. The article describes the systematic identification of neutralizing and non-neutralizing B-cell epitopes on ricin toxin's enzymatic A subunit (RTA). An inactivated form of RTA is the primary component of RiVax(TM), the Company's proprietary vaccine against ricin...

2010-08-24 07:00:00

CHICAGO, Aug. 24 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced plans to seek additional government funding for development of its novel, once-daily antibiotic, Restanza(TM) (cethromycin) based on a new, high-profile report from the Department of Health...

2010-08-06 07:40:00

CHANTILLY, Va., Aug. 6 /PRNewswire/ -- Rashid Chotani, M.D., M.P.H., has joined TASC, Inc. as director of Chemical-Biological Defense Programs. In this role, Chotani will lead chemical and biological programs that support the Defense Threat Reduction Agency (DTRA), U.S. Army and the Office of the Secretary of Defense, as well as civilian agencies such as Department of Homeland Security, National Institutes of Health and the Centers for Disease Control. (Logo:...

2010-07-08 07:00:00

ANNAPOLIS, Md., July 8 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE: Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it continues to make solid progress in its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine development program. The Company has recently demonstrated that its lyophilized rPA vaccine candidate is structurally stable and potent at various temperatures up to and including 70...

2010-06-25 06:00:00

PRINCETON, N.J., June 25 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today the publication of an article in the June 2010 edition of Vaccine, which describes protection from mucosal and systemic ricin intoxication by intradermal administration of RiVax(TM), the Company's vaccine against ricin toxin. The article was authored by the Company's collaborators at the University of Texas...